Literature DB >> 22374333

cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Kanwal P Raghav1, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N Hortobagyi, Gordon B Mills, Funda Meric-Bernstam, George R Blumenschein, Ana M Gonzalez-Angulo.   

Abstract

PURPOSE: To evaluate cMET (mesenchymal-epithelial transition factor gene) and phospho-cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes. EXPERIMENTAL
DESIGN: We measured protein levels of cMET and p-cMET in 257 breast cancers using reverse phase protein array. Regression tree method and Martingale residual plots were applied to find best cutoff point for high and low levels. Kaplan-Meier survival curves were used to estimate relapse-free (RFS) and overall (OS) survival. Cox proportional hazards models were fit to determine associations of cMET/p-cMET with outcomes after adjustment for other characteristics.
RESULTS: Median age was 51 years. There were 140 (54.5%) hormone receptor (HR) positive, 53 (20.6%) HER2 positive, and 64 (24.9%) triple-negative tumors. Using selected cutoffs, 181 (70.4%) and 123 (47.9%) cancers had high levels of cMET and p-cMET, respectively. There were no significant differences in mean expression of cMET (P < 0.128) and p-cMET (P < 0.088) by breast cancer subtype. Dichotomized cMET and p-cMET level was a significant prognostic factor for RFS [HR: 2.44, 95% confidence interval (CI): 1.34-4.44, P = 0.003 and HR: 1.64, 95% CI: 1.04-2.60, P = 0.033] and OS (HR: 3.18, 95% CI: 1.43-7.11, P = 0.003 and HR: 1.92, 95% CI: 1.08-3.44, P = 0.025). Within breast cancer subtypes, high cMET levels were associated with worse RFS (P = 0.014) and OS (P = 0.006) in HR-positive tumors, and high p-cMET levels were associated with worse RFS (P = 0.019) and OS (P = 0.014) in HER2-positive breast cancers. In multivariable analysis, patients with high cMET had a significantly higher risk of recurrence (HR: 2.06, 95% CI: 1.08-3.94, P = 0.028) and death (HR: 2.81, 95% CI: 1.19-6.64, P = 0.019). High p-cMET level was associated with higher risk of recurrence (HR: 1.79, 95% CI: 1.08-2.95.77, P = 0.020).
CONCLUSIONS: High levels of cMET and p-cMET were seen in all breast cancer subtypes and correlated with poor prognosis. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22374333      PMCID： PMC3821167          DOI： 10.1158/1078-0432.CCR-11-2830

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  49 in total

1.  Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.

Authors:  L Beviglia; K Matsumoto; C S Lin; B L Ziober; R H Kramer
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma.

Authors:  G Edakuni; E Sasatomi; T Satoh; O Tokunaga; K Miyazaki
Journal:  Pathol Int       Date:  2001-03       Impact factor: 2.534

3.  Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.

Authors:  Yasuyoshi Miyata; Hiroshi Kanetake; Shigeru Kanda
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

4.  Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

Authors:  Stephen Hiscox; Nicola J Jordan; Wen Jiang; Maureen Harper; Richard McClelland; Chris Smith; Robert I Nicholson
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

5.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

6.  Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.

Authors:  Yasuyoshi Miyata; Yuji Sagara; Shigeru Kanda; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Hum Pathol       Date:  2009-01-03       Impact factor: 3.466

7.  Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents.

Authors:  S Fan; J A Wang; R Q Yuan; S Rockwell; J Andres; A Zlatapolskiy; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

8.  HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Authors:  Hanane Khoury; Monica A Naujokas; Dongmei Zuo; Veena Sangwan; Melanie M Frigault; Stephanie Petkiewicz; David L Dankort; William J Muller; Morag Park
Journal:  Mol Biol Cell       Date:  2004-11-17       Impact factor: 4.138

9.  Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells.

Authors:  V Brinkmann; H Foroutan; M Sachs; K M Weidner; W Birchmeier
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

10.  Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

Authors:  E Ichimura; A Maeshima; T Nakajima; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1996-10
View more
  53 in total

1.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

2.  H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism.

Authors:  Mei-Kuang Chen; Yi Du; Linlin Sun; Jennifer L Hsu; Yu-Han Wang; Yuan Gao; Jiaxing Huang; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

3.  Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

Authors:  Debora de Melo Gagliato; Denis L Fontes Jardim; Gerald Falchook; Chad Tang; Ralph Zinner; Jennifer J Wheler; Filip Janku; Vivek Subbiah; Sarina A Piha-Paul; Siqing Fu; Kenneth Hess; Sinchita Roy-Chowdhuri; Stacy Moulder; Ana M Gonzalez-Angulo; Funda Meric-Bernstam; David S Hong
Journal:  Clin Breast Cancer       Date:  2014-06-23       Impact factor: 3.225

4.  Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.

Authors:  Yangfeng Li; Jiong Zhao; Lauren M Gutgesell; Zhengnan Shen; Kiira Ratia; Katherine Dye; Oleksii Dubrovskyi; Huiping Zhao; Fei Huang; Debra A Tonetti; Gregory R J Thatcher; Rui Xiong
Journal:  J Med Chem       Date:  2020-06-15       Impact factor: 7.446

5.  c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.

Authors:  Mariana Fathy Gayyed; Nehad M R Abd El-Maqsoud; Amr Abd El-Hameed El-Heeny; Mostafa Fuad Mohammed
Journal:  J Gastrointest Oncol       Date:  2015-12

6.  Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

Authors:  K Kalinsky; T Zheng; H Hibshoosh; X Du; P Mundi; J Yang; S Refice; S M Feldman; B Taback; E Connolly; K D Crew; M A Maurer; D L Hershman
Journal:  Clin Transl Oncol       Date:  2016-06-15       Impact factor: 3.405

Review 7.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

8.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

Review 9.  MET deregulation in breast cancer.

Authors:  Gabriele Minuti; Lorenza Landi
Journal:  Ann Transl Med       Date:  2015-08

10.  Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.

Authors:  Mario Niepel; Marc Hafner; Emily A Pace; Mirra Chung; Diana H Chai; Lili Zhou; Birgit Schoeberl; Peter K Sorger
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.